

Original Research

Effect of Physical Position on Peak Inspiratory Flow in Stable COPD: An Observational Study

Roy A. Pleasants,^{1,2} Ashley G. Henderson,³ Valentina Bayer,⁴ Asif Shaikh,⁴ M. Bradley Drummond³

¹Marsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

²Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan, United States

³Division of Pulmonary Diseases and Critical Care Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

⁴Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, United States

Address correspondence to:

Roy A. Pleasants, PharmD
University of North Carolina at Chapel Hill
Chapel Hill, NC
Phone: (919) 843-9938
Email: pleas005@email.unc.edu

Running Head: Physical Position Effect on Peak Inspiratory Flow

Keywords: peak inspiratory flow rate; dry powder inhalers; chronic airways obstruction; inhalation technique

Abbreviations: BD: Bronchodilator; BMI: Body mass index; CAT: COPD Assessment Test; CI: Confidence interval; COPD: Chronic obstructive pulmonary disease; DPI: Dry powder inhaler; FEV₁: Forced expiratory volume in 1 second; FVC: Forced vital capacity; GOLD: Global Initiative for Chronic Obstructive Lung Disease; IQR: Interquartile range; pMDI: Pressurized metered-dose inhaler; mMRC: Modified Medical Research Council; PIF: Peak inspiratory flow; PIFR: PIF rate; Q-Q: Quantile-quantile; R2: Low-medium resistance; R5: High resistance; SD: Standard deviation; UNC-CH: University of North Carolina at Chapel Hill

Funding Support: This research was funded by Boehringer Ingelheim Pharmaceuticals Inc (BIPI). BIPI was given the opportunity to review the manuscript for medical and scientific

accuracy, as it relates to BIPI substances as well as intellectual property considerations.

Date of Acceptance: December 12, 2023 | ***Publication Online Date:*** January 16, 2024

Citation: Pleasants RA, Henderson AG, Bayer V, et al. Effect of physical position on peak inspiratory flow in stable COPD: an observational study. *Chronic Obstr Pulm Dis*. 2024; Published online January 17, 2024. <https://doi.org/10.15326/jcopdf.2023.0460>

This article has an online supplement.

Pre-proof

Abstract

Background: We examined the effect of physical position on peak inspiratory flow (PIF) in patients with chronic obstructive pulmonary disease (COPD) using dry powder inhalers (DPIs) with low-medium (R2) and/or high (R5) internal resistance.

Methods: This prospective study in stable, ambulatory patients with spirometry-confirmed COPD evaluated the effect of three physical positions on maximal PIF achieved. Participants had PIF of 30–90 L/min (R5) or 60–90 L/min (R2 DPIs) using the In-Check™ DIAL. PIF was measured in triplicate randomly in three positions that patients might be in while using their inhaler (standing, sitting, and semi-upright [supine position with head of bed at 45°, neck flexed forward]) against prescribed DPI resistance (R2/R5/both). Correlations between PIF and percent decline in PIF between positions and differences in participant characteristics with >10% vs. ≤10% PIF decline standing to semi-upright were calculated.

Results: Seventy-six participants (mean age, 65.2 years) had positional measurements; 59% reported seated DPI use at home. Mean (standard deviation) PIF standing, sitting, and semi-upright was 80.7 (13.4), 77.8 (14.3), and 74.0 (14.5) L/min, respectively, for R2 and 51.1 (9.52), 48.6 (9.84), and 45.8 (7.69) L/min, respectively, for R5 DPIs. PIF semi-upright was significantly lower than sitting and standing (R2; $P < 0.0001$) and standing (R5; $P = 0.002$). Approximately half had >10% decline in PIF from standing to semi-upright. Patient characteristics exceeding the 0.10 absolute standardized difference threshold with the decline in PIF for both the R2 and R5 DPIs were waist-to-hip ratio, modified Medical Research Council dyspnea score, and post-bronchodilator % predicted forced vital capacity and PIF by spirometry.

Conclusions: PIF was significantly affected by physical position regardless of DPI resistance. PIF was highest when standing and lowest when semi-upright. We recommend patients with COPD stand while using an R2 or R5 DPI. Where unfeasible, the position should be sitting rather than semi-upright.

Trial registration: ClinicalTrials.gov identifier NCT04168775; Trial registration date: November 19, 2019

1. Introduction

Chronic obstructive pulmonary disease (COPD) represents one of the top three causes of death globally [1], affecting approximately 380 million people [2]. It is a major public health challenge [1] with a significant economic burden [2] that is projected to increase primarily because of continued exposure to COPD risk factors and population aging [3]. Improved long-term management of COPD is key to reducing mortality and morbidity, as well as lowering the economic impact, which is primarily related to hospital admissions for exacerbations [4].

The primary treatment modalities for COPD after smoking cessation and environmental/occupational exposure avoidance include the administration of inhaled medications. These medications can be delivered through multiple mechanisms, including pressurized metered-dose inhalers (pMDIs), dry powder inhalers (DPIs), soft mist inhalers (SMIs), or nebulizers [3]. DPIs, which account for more than 35% of the global inhaler market [5], are breath-actuated devices with varying levels of internal resistance [6]. While many factors may impact the effective delivery of medication to the lungs with a DPI, users must overcome the internal resistance of the DPI by achieving peak inspiratory flow (PIF), defined as the maximal flow rate, typically expressed in L/min, obtained during an inspiratory maneuver [6]. Low PIF may negatively impact drug delivery to the lungs via DPIs [7] and has been associated with poor patient outcomes [8] and higher COPD-related healthcare utilization and costs [9].

Practical and standardized recommendations for measuring PIF in patients with COPD using DPIs are lacking [6], including whether the patient's physical position affects the maximal inspiratory effort achieved. Previous studies have shown the association of modifiable factors with improved pulmonary function [6,8,10], including PIF assessed by

spirometry or portable inspiratory devices; however, there remains a paucity of information about the modifiable factors affecting PIF in patients with COPD. Moreover, despite the evidence that physical position may influence pulmonary function [11], the association of PIF with physical position during DPI use in patients with COPD remains unknown. The effect of physical position on maximum inspiratory effort may be most significant during severe exacerbations when patients' lung function is severely impaired, and they often receive inhaled medications in the semi-recumbent position.

In a group of stable outpatients with COPD, we investigated whether different physical positions, specifically, the semi-upright position commonly used in acute care settings and the sitting and standing positions typically used in the ambulatory setting, affected PIF (InCheck[®] DIAL, Clement Clarke International, UK). To the best of our knowledge, this has not been reported previously.

2. Methods

2.1. Study design

Data for this exploratory analysis were extracted from a single visit occurring as part of a larger prospective, observational, 24-week study conducted in stable, ambulatory adults with COPD using a DPI (NCT04168775). The University of North Carolina at Chapel Hill (UNC-CH) Institutional Review Board reviewed and approved the protocol, informed consent forms, and other relevant documents (IRB# 19-0450). All participants provided written informed consent.

2.2. Participants

Adults aged >50 years with COPD seen at the UNC-CH outpatient pulmonary clinics who were either current or former smokers (>10 pack-years of smoking) were eligible to

participate. Other eligibility criteria were as follows: spirometry-confirmed diagnosis of COPD (post-bronchodilator forced expiratory volume in 1 second/forced vital capacity [FEV₁/FVC] <0.70), COPD at Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages II–IV based on existing spirometry results, COPD Assessment Test (CAT) score >10, ≥ 1 COPD exacerbation requiring systemic corticosteroids within the last three years, stable COPD (no recent exacerbation in the past 30 days), and PIF of 60–90 L/min against R2 DPIs (low-medium resistance inhalers e.g. Diskus[®], Ellipta[®]) or 30–90 L/min against R5 DPIs (high resistance inhalers e.g. Handihaler[®]), depending upon the prescribed maintenance inhaler device using the In-Check[™] DIAL to assess PIF [12]. The key exclusion criteria were inability to demonstrate proper technique for the In-Check[™] DIAL device; inability to achieve minimum PIF rate (PIFR) for the prescribed DPI(s) at the screening/enrollment visit (e.g., <30 L/min, for Handihaler[®] [high-resistance DPI], <60 L/min for Ellipta[®] [medium-resistance DPI]); and neuromuscular disease associated with weakness.

2.3. PIF measurement

PIF was measured for each subject in three positions: standing, sitting, and semi-upright (supine with the head of the bed at 45° and their neck flexed forward), and all measurements were taken at the same visit. Measurements were taken in a random order with regard to the physical position. For each physical position, PIF was measured in triplicate with the highest of the three measurements used for analysis [6]. The In-Check[™] DIAL is a handheld respiratory flow–measurement device designed to simulate the resistance of inhaler devices from the DPI and metered-dose inhaler categories, which enables clinicians to coach patients to use more or less inspiratory flow to achieve optimal flow rates [13]. The In-Check[™] DIAL was set according to manufacturer’s recommendations using the resistance of

the inhaler(s) that the patients were using at home (R2, for patients who were using R2 resistance; R5, for patients who were using R5; or both, for patients who were using both R2 and R5 inhalers). The participant's bronchodilators were withheld prior to the visit and positional PIF measurements were performed before bronchodilator (BD) reversibility testing with spirometry. Pre- and post-spirometry were performed concurrent to pre- and post-PIF measurements, with each test done in at least triplicate to meet The American Thoracic Society/European Respiratory Society spirometry guidelines [14]. In contrast to R2 and R5 resistance settings on the InCheck[®]DIAL device, the resistance to inhalation is essentially zero with a spirometer. Participants were directed with each PIF measurement to follow manufacturer instructions for the InCheck[®]DIAL by exhaling slowly and completely, followed immediately by a rapid ("as fast as possible") and maximal inhalation ("until you cannot inhale anymore") [6]. Participants' PIF was measured against an R2 DPI if their home inhaler was R2, an R5 DPI if their home inhaler was R5, and both R2 and R5 DPIs if they used both types of inhalers at home. If a patient was using both R2 and R5 DPIs, both R2 and R5 positional measurements contributed to the data. Positional PIF measurements were taken at a single time point during the study, either at week 1 (enrollment) or week 24. These time points were selected due to the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 [COVID-19]) virus on the study design.

Participants were asked at the outset of the study about how they most commonly administered their DPIs with respect to physical position when at home; the screening of PIF for study eligibility was performed based on each participant's reported physical positions at home. We also measured the waist-to-hip ratio [15] to determine whether central adiposity might influence PIF among the different positions. For post-BD spirometry measurements, the BD was administered as four puffs of albuterol with a spacer, and lung function tests were repeated 15–20 minutes later.

2.4. Statistical analysis

For this analysis, it was hypothesized that PIF would be reduced in patients in the semi-upright position vs. the sitting and standing positions. This was an exploratory analysis, and consequently, no formal power calculations were conducted. Descriptive statistics were used to summarize the clinical and pulmonary baseline function characteristics. Data are presented as mean (standard deviation [SD]), median (interquartile range [IQR]), or n (%). Baseline demographic, clinical, and pulmonary characteristics were stratified by inhaler device type at enrollment; however, no statistical analyses were performed as the groups were not assigned *a priori*. Differences in PIF between positions were assessed using a paired *t*-test (p-values were not corrected for multiple comparisons). Normality of distributions was assessed using quantile-quantile (Q-Q) plots and the Shapiro-Wilk test. The percentage decline in the positions for each DPI type was calculated as follows:

standing to sitting = $[(PIF_{standing} - PIF_{sitting}) / PIF_{standing}] * 100$;

standing to semi-upright = $[(PIF_{standing} - PIF_{semi-upright}) / PIF_{standing}] * 100$; and

sitting to semi-upright = $[(PIF_{sitting} - PIF_{semi-upright}) / PIF_{sitting}] * 100$.

The demographic and clinical characteristics of participants with a >10% and ≤10% PIF decline from standing to semi-upright positions were compared and are presented as mean (SD) or n (%) and associated standardized difference, which is a qualitative description of differences. There is no known minimum clinically important difference for PIF. The 10% threshold was selected because it was outside the reported variation of the In-Check™ DIAL and aligned with the magnitude of change observed in bronchodilator testing [6,13]. An absolute standardized difference of ≥0.10 or ≤-0.10 indicates a potential imbalance in covariates between groups [16].

The distribution of PIF data is graphically presented using box and whiskers and scatter plots. The Spearman correlation coefficients of PIF for pairs of physical positions were calculated. All analyses were independently completed by one of the authors (MBD) using Stata version 16.1 (College Station, Texas).

3. Results

3.1. Participants

Between July 31, 2019, and November 9, 2021, 96 participants were screened for the study and 80 were subsequently enrolled, with 76 participants contributing positional PIF data. Of the excluded patients, 10 did not achieve PIF in the target range, while the remainder did not use the prescribed DPI or had a CAT score <10 . The baseline demographic, clinical, and pulmonary characteristics of participants with positional data are shown in Table 1. The mean (SD) age was 65.2 (8.77 years) years. Forty-two (55%) participants were female, most were White ($n = 66$; 87%), and 27 (36%) and 49 (64%) were current and former smokers, respectively. The mean (SD) body mass index (BMI) was 28.8 (7.26) kg/m^2 ; 28 (36.84%) patients were obese ($\text{BMI} \geq 30 \text{ kg/m}^2$) and 4 (5%) were severely obese ($\text{BMI} \geq 40 \text{ kg/m}^2$). When using a DPI at home, 45 (59%) participants reported normally using a sitting position and 31 (41%) a standing position. The mean predicted pre- and post-BD FEV_1 was 45% and 48.7%, respectively. The mean (SD) pre-BD PIF was 182 (67.2) L/min (by spirometry) and 69 (15.4) L/min (by In-Check™ DIAL), and 179 (72.8) L/min (by spirometry) and 75.3 (16.6) L/min (by In-Check™ DIAL) post-BD. Fifty-seven participants (75%) were using R2 DPIs only at home, 13 (17%) were using R5 DPIs only, and six (8%) were using both. Overall, patients using R5 DPIs were younger and had a lower BMI, higher CAT score, and lower lung function compared with those using R2 DPIs alone or R2 and R5 DPIs (Supplementary Table 1).

3.2. Correlation of PIF for physical positions

The median (IQR) PIF for participants in each physical position using the R2 and R5 DPIs is shown in Fig. 1. For participants using R2 DPIs, the median (IQR) PIF in the standing, sitting, and semi-upright positions was 80 (70–88), 78 (66–85), and 75 (63–80) L/min, respectively, and the mean (SD) PIF was 80.7 (13.4), 77.8 (14.3), and 74.0 (14.5), respectively. For participants using R5 DPIs, the median (IQR) PIF in the standing, sitting, and semi-upright positions was 50 (47–59), 50 (43–56), and 46 (39–52) L/min, respectively, and the mean (SD) PIF was 51.1 (9.52), 48.6 (9.84), and 45.8 (7.69) L/min, respectively. In all three physical positions, the mean and median PIF for participants using an R2 DPI was higher than that for participants using an R5 DPI. For participants using R2 DPIs, the PIF in the semi-upright position was significantly lower than that in the sitting and standing positions ($P < 0.0001$). For participants using R5 DPIs, the PIF in the semi-upright position was significantly lower than that in the standing position ($P = 0.002$). All positional measurements for both the R2 and R5 DPIs were normally distributed (data not shown).

The correlation of PIF for pairs of physical positions (standing vs. sitting, standing vs. semi-upright, and sitting vs. semi-upright) for participants using R2 and R5 DPIs is shown in Fig. 2. In all physical positions, the PIF for participants using an R2 DPI was higher than that for participants using an R5 DPI. The PIF correlations for participants using R2 DPIs were as follows: standing vs. sitting, Spearman's rho 0.875 ($P < 0.0001$); standing vs. semi-upright, Spearman's rho 0.887 ($P < 0.0001$); and sitting vs. semi-upright, Spearman's rho 0.888 ($P < 0.0001$). Furthermore, the PIF correlations for participants using R5 DPIs were as follows: standing vs. sitting, Spearman's rho 0.7132 ($P = 0.0006$); standing vs. semi-upright, Spearman's rho 0.717 ($P = 0.0005$); and sitting vs. semi-upright, Spearman's rho 0.682 ($P = 0.0013$).

Owing to changes in visit structure as a result of the COVID-19 pandemic, a total of 29 participants (38% of the analytical cohort) had positional data measured at the enrollment visit, while 47 participants (62% of the analytical cohort) had positional data measured at study completion (week 24). On reviewing the PIF values stratified by timing of positional data collection, no consistent and meaningfully higher PIF values among those completing measurements at the final study visit were observed, suggesting no impact of training effect on the study findings.

3.3. *PIF change with physical position*

The number (%) of participants with a >10%, >15%, and >20% decline in PIF between pairs of physical positions was calculated for R2 and R5 DPIs, and the percentage decline in PIF is shown in Table 2. Approximately half of the participants had a >10% decrease in PIF from the standing to semi-upright positions for R2 (n = 31; 50%) and R5 (n = 10; 53%) DPIs, and 11 (18%; R2) and six (32%; R5) participants had a >10% decrease in PIF from the sitting to semi-upright positions. A small percentage of participants had a decline of >15% or >20% for both R2 and R5, with the largest proportion in the standing to semi-upright positional change. Two participants using R5 DPIs and 1 patient using an R2 DPI reported >50% difference between standing and semi-upright positions.

Of note, the proportion of patients using R2 DPIs who did not reach optimal PIF (<60 L/min) for R2 were 1.3% (n=1 of 76), 6.6% (n=5 of 76), and 10.5% (n=8 of 76) for the standing, sitting, and semi-upright positions, respectively. All patients using R5 DPIs reached optimal PIF (>30 L/min).

3.4. Differences in the demographic and clinical characteristics in participants with PIF decline >10% vs. ≤10% from the standing to semi-upright positions

We examined the differences in demographic and clinical characteristics between participants with a decline in PIF from the standing to semi-upright positions (>10% vs. ≤10%); Tables 3 and 4. This threshold was also chosen because it was outside the reported variation of the In-Check™ DIAL and aligned with the magnitude of change observed in bronchodilator testing. Approximately half of the participants using R2 or R5 DPIs exhibited a >10% decline in PIF from the standing to semi-upright positions (50% and 53%, respectively). The mean BMI did not differ between patients with a >10% decline vs. those with a ≤10% decline when standing to semi-upright using an R2 or R5 device, although there was a greater proportion of obese patients (BMI: ≥30 kg/m²) in the >10% vs. ≤10% group among those using R5 DPIs (40% vs. 33%). A >10% decline in patients using R2 or R5 DPIs was associated with a lower waist-to-hip ratio compared with those who had a ≤10% decline.

Several clinical characteristics exceeded the 0.10 absolute standardized difference threshold with the decline in PIF using R2 DPIs, including age, sex (female), waist-to-hip ratio, modified Medical Research Council (mMRC) score, pre-BD FEV₁/FVC ratio and PIF by spirometry, post-BD FEV₁/FVC ratio and PIF by spirometry, % predicted FEV₁, % predicted FVC. The characteristics that had their absolute standardized threshold for R2 DPIs below the −0.10 threshold were current smokers, CAT score, and pre-BD absolute (L) FEV₁ and absolute (L) FVC (Table 3).

Participant characteristics that exceeded the 0.10 standardized difference threshold with R5 DPIs included waist-to-hip ratio, pack-years smoked, CAT score, mMRC score, and pre- and post-BD absolute (L) FEV₁, absolute (L) FVC, % predicted FVC, and PIF by

spirometry and In-Check™ DIAL. Characteristics that had their absolute standardized threshold for R5 DPIs below the −0.10 threshold were race (White), sex (female), higher BMI obesity category, and pre- and post-BD FEV₁/FVC ratios (Table 4).

4. Discussion

This study showed for the first time in a stable COPD population that PIF measurement using an inspiratory flow meter is affected by the patient's physical position. Mean PIF was the highest in the standing position and lowest in the semi-upright position. Approximately half of the participants had a >10% decline in PIF from the standing to semi-upright position, and nearly one-third exhibited ≥15% decline in PIF with the higher resistance setting. Several demographic and clinical characteristics were imbalanced between participants with a PIF decline >10% vs. ≤10% from standing to semi-upright, including sex (female), FVC, and smoking status. These findings have important implications for guiding patients on optimal techniques to maximize PIF when using DPIs by reinforcing the importance of standing or sitting (where possible), rather than adopting a semi-upright position. This is especially true during exacerbations, as PIF and other inspiratory lung function measures are known to be substantially reduced [17]. We also report, for the first time, the typical physical positions adopted by individual patients with COPD when self-administering their DPIs at home.

In the current study, the PIF for participants using the R2 DPI was higher than that for participants using the R5 DPI in all physical positions. There was a strong correlation between standing, sitting, and semi-upright measurements of PIF for participants using R2 and R5 DPIs. Dal Negro examined whether DPIs at different intrinsic resistance regimens (low, medium, and high) were affected by changes in lung function and/or could be predicted by specific lung function parameters in patients with asthma, COPD, or restrictive lung disease [18]. The study showed that patients with asthma or COPD using medium-resistance

DPI regimens were more likely to achieve the expected PIF level than those using low- or high-resistance DPI regimens. Thus, DPI resistance can significantly influence PIF [19]. Our study also suggests that DPI resistance, in combination with the physical position adopted when using a DPI, may impact PIF.

When using a DPI at home, 45 (59%) participants reported using a sitting position and 31 (41%) reported using a standing position. We assume that this preference for sitting or standing may apply for other inhalers as well. Our findings can inform instructions given to patients using an R2 or R5 DPI, recommending that they stand when possible. Given that this approach may not be possible in hospitals or nursing homes due to safety and convenience concerns, or at home due to safety and physical-impairment concerns, the recommended position should be sitting rather than lying down (semi-upright) if possible. Furthermore, in cases where the PIF is significantly impaired, the use of a wet aerosol inhaler or nebulizer may be preferable. While decreased efficacy due to suboptimal PIF with DPIs has been reported [20], the impact of low inhalational flow rates and subsequently increased oral deposition on oropharyngeal side effects of inhaled corticosteroids remains unclear. A real-world study reported that patients using fluticasone propionate/salmeterol DPIs were more likely to report oral candidiasis than those using the pMDI formulation [19].

Prior studies employing spirometry have examined the effects of physical position on expiratory flow measurements [21–23]. The position of the head and its relationship with airflow in respiration was described as early as 1959 [24]. Harris found a statistically significant difference in the forced inspiratory volume achieved within the first 0.5 seconds when the head was flexed compared with when it was fully extended [24]. Numerous recent studies have shown that gross postural changes affect pulmonary function, with standing and sitting leading to the highest lung volumes [11]. Physical position changes have been shown

to affect individuals with normal lung function, with a mean decrease in FVC from sitting to supine of around 7% [25]. Decreased maximum inspiratory pressure, which correlates well with PIF in COPD [26], observed in the semi-upright position could be related to diaphragm overload by abdominal content displacement during maximal inspiratory effort [11]. This effect may offset the improved diaphragm function associated with the position, allowing for an optimal length-tension relationship in the diaphragmatic muscle fibers. Furthermore, lengthening of other inspiratory muscles may become restricted in the semi-upright position [11]. Indeed, the “tripod position,” a seated position where the trunk is leaning forward with the arms braced on the knees, is adopted by individuals to relieve dyspnea in severe COPD [10,27]. Studies have shown that this position enables accessory muscles, such as the pectoralis major and minor, to significantly contribute to rib cage elevation [28].

Additionally, adopting a seated, forward-leaning posture is associated with an improved ability to generate maximal inspiratory pressure, improved length-tension relationships and neuromechanical efficiency of the diaphragm, and reduced neuromechanical dissociation of the respiratory system [29]. Lifting the chin while using DPIs is often recommended for more efficient passage of the drug into the lungs; this may not be possible in the semi-upright position. In the current study, participants who were in the semi-upright position at 45° with their head held forward to where the neck was near vertical (more flexed than extended) had lower PIF than those in the standing or sitting position. Moreover, we found that approximately half of the participants had a >10% drop from the standing to semi-upright position. A small number of participants showed large differences between these two positions. No clear, minimally important clinical difference has been established for PIF. While this study was not designed to correlate the impact of positional changes in PIF to clinical outcomes or drug delivery, these findings suggest that positional modifications (i.e., standing rather than being semi-upright or sitting) may be an approach to improve PIF.

Body habitus (obesity and waist-to-hip ratio) could have a differential impact on PIF based on participant position. In this study, we did not observe a difference in the mean BMI between those with a $>10\%$ decline and those with a $\leq 10\%$ decline from the standing to semi-upright positions. Therefore, it does not appear that obesity or central adiposity, when combining males and females, were substantial drivers in the observed positional changes in PIF.

Achieving an adequate PIF with DPIs is considered vital for optimizing aerosol drug delivery in the COPD population. While a maximal inhalation is desirable to disaggregate the dry powder in the inhaler to achieve optimal particle size, it is possible that excessively rapid inhalation with a DPI might increase oropharyngeal deposition. Studies comparing aerosol delivery with the same DPI at rapid versus slow, forceful inhalation and resultant oropharyngeal deposition have not been reported to our knowledge. One study in children found that more rapid (higher) inhalation rates resulted in greater improvement in FEV₁ [30]. Additionally, differences in instructions on proper inhalation technique for DPIs with the same degree of internal resistance do exist (e.g., Diskus[®] inhaler [31] instructions recommend deep, rapid inhalation while instructions for the Ellipta[®] inhaler [32] recommend full, complete inhalation). However, an expert group recommends a deep, forceful inhalation for DPIs [6].

This is the first study to measure PIF in different physical positions in a standardized manner, and to the best of our knowledge, there are little data published on this topic. The recommendations from our study are straightforward and practical to implement. Ideally, patients should have their PIF measured, but it is often not performed in routine clinical practice. Consideration of physical position is an easily modifiable factor that can be realistically performed by patients in a clinical or home setting with proper guidance.

Furthermore, our approach of randomizing the sequence of positions of PIF measurements decreased the chances of individual training effects during repeated measures.

The current study has some limitations. The sample size and single-center setting of the study may limit the generalizability of the results; moreover, being an observational study, it may be prone to bias. The timing of PIF measurements and spirometry, which was impacted by the COVID-19 pandemic, occurred at two different time points in the study (some at the start of the study and some at the end), and, therefore, may have introduced variability into the data; however, our findings suggest no consistent or meaningful impact of the timing of positional data collection on study results. It is also possible that patients with prior experience with the InCheck[®] DIAL inspiratory flow meter use may have performed differently than those naïve to the device. Additionally, the PIF measured within the study setting may be higher than that recorded in real-life settings, as participants were performing inhalation maneuver under supervision. Follow-up studies could include measurements of pulmonary function, including lung volume, which would further inform the findings of the current study. Additional clinical trials examining PIF measurements in hospitalized patients who are positioned semi-upright and receive DPIs vs. no DPIs may be warranted.

5. Conclusions

In a stable COPD population, PIF was the lowest in the semi-upright position, regardless of the resistance and type of DPI used. This study highlights the importance of the physical position adopted during the DPI inhalation maneuver and in measuring PIF in patients with COPD. Our findings provide further evidence in favor of standardizing the physical positioning during DPI use to ensure adequate drug delivery to the lungs and superior patient outcomes. The findings of the current study may inform instructions given to

patients with COPD when using DPIs, especially in a hospital, nursing home, or an outpatient setting. Previously unreported, almost 60% of participants indicated that they normally used their DPIs while sitting. It is recommended that patients stand while using an R2 or R5 DPI when possible. When this approach is not possible, the recommended position should be sitting rather than semi-upright.

DECLARATIONS

Ethics approval and consent to participate

The University of North Carolina at Chapel Hill (UNC-CH) Institutional Review Board reviewed and approved the protocol, informed consent forms, and other relevant documents (IRB# 19-0450). All participants provided written informed consent, and all study procedures were carried out in accordance with the relevant guidelines and regulations as outlined by the UNC-CH Institutional Review Board and the Declaration of Helsinki.

Consent for publication

Not applicable.

Availability of data and materials

The data are not publicly available due to the small study size and single-center setting, which could compromise the privacy of the research participants. Data requests should be sent to the author (MBD). Restrictions may apply to the availability of these data, which were generated under an agreement with the funder. Data requests will need to align with the university and funder policies prior to release and will be accepted only with the permission of the funder.

Author contributions

RAP substantially contributed to the conception and design of the study, data acquisition, and drafting and revision of the manuscript. AGH contributed substantially to the conception and design of the study, data acquisition, and drafting and revision of the manuscript. VB contributed substantially to the design of the study, review of data analysis and interpretation, and drafting and revision of the manuscript. AS contributed substantially to the conception and design of the study, data analysis, and drafting and revision of the manuscript. MBD contributed substantially to the conception and design of the study, data acquisition, data analysis, and drafting and revision of the manuscript. MBD takes sole responsibility for data analyses. All authors (RAP, AGH, VB, AS, and MBD) approved the final version of the manuscript.

Acknowledgments

This research was funded by Boehringer Ingelheim Pharmaceuticals Inc (BIPI). BIPI was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations.

The authors meet the criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors received no direct compensation related to the development of this manuscript.

Writing, editorial support, and formatting assistance for this manuscript were provided by Nicola Welch, PhD, CMPP, for Cactus Life Sciences (part of Cactus Communications), which was contracted and compensated by BIPI for these services.

Pre-proof

References

- [1] Global Initiative for Chronic Obstructive Lung Disease (GOLD) [Internet]. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: updated 2023; 2023 [cited 2023 Feb 1]. Available from: <https://goldcopd.org/2023-gold-report-2/>
- [2] I. Iheanacho, S. Zhang, D. King, M. Rizzo, A.S. Ismaila, Economic burden of chronic obstructive pulmonary disease (COPD): a systematic literature review, *Int. J. Chron. Obstruct. Pulmon. Dis.* 15 (2020) 439–460, <https://doi.org/10.2147/COPD.S234942>.
- [3] D.P. Tashkin, A review of nebulized drug delivery in COPD, *Int. J. Chron. Obstruct. Pulmon. Dis.* 11 (2016) 2585–2596, <https://doi.org/10.2147/COPD.S114034>.
- [4] S. M. May, J. T. Li. Burden of chronic obstructive pulmonary disease: healthcare costs and beyond. *Allergy Asthma Proc.* 36 (2015) 4–10. doi: 10.2500/aap.2015.36.3812.
- [5] Dry Powder Inhaler Market 2022. <https://www.factmr.com/report/dry-powder-inhaler-market, 2021> (Accessed 28 February 2022).
- [6] J.A. Ohar, G.T. Ferguson, D.A. Mahler, M.B. Drummond, R. Dhand, R.A. Pleasants, et al., Measuring peak inspiratory flow in patients with chronic obstructive pulmonary disease, *Int. J. Chron. Obstruct. Pulmon. Dis.* 17 (2022) 79–92, <https://doi.org/10.2147/COPD.S319511>.
- [7] S.Y, Chen, C.K. Huang, H.C. Peng, C.J. Yu, J.Y. Chien, Inappropriate peak inspiratory flow rate with dry powder inhaler in chronic obstructive pulmonary disease, *Sci. Rep.* 10 (2020) 7271, <https://doi.org/10.1038/s41598-020-64235-6>.
- [8] J.S. Alqahtani, Y.S.Aldabayan, A.M.Aldhahir, A.M.Al Rajeh, S.Mandal, et al. Predictors of 30- and 90-Day COPD exacerbation readmission: A prospective cohort study. *Int J Chron Obstruct Pulmon Dis.* 16 (2021) 2769–2781. doi: 10.2147/COPD.S328030.

- [9] M.T. Leving, J.F.M. van Boven, S.Z. Bosnic-Anticevich, J. van Cooten, J. Correia de Sousa, B. Cvetkovski, et al., Suboptimal peak inspiratory flow and critical inhalation errors are associated with higher COPD-related healthcare costs, *Int. J. Chron. Obstruct. Pulmon. Dis.* 17 (2022) 2401–2415, <https://doi.org/10.2147/COPD.S380736>.
- [10] K.S. Kim, M.K. Byun, W.H. Lee, H.S. Cynn, O.Y. Kwon, C.H. Yi, Effects of breathing maneuver and sitting posture on muscle activity in inspiratory accessory muscles in patients with chronic obstructive pulmonary disease, *Multidiscip. Respir. Med.* 7 (2012) 9, <https://doi.org/10.1186/2049-6958-7-9>.
- [11] S. Katz, N. Arish, A. Rokach, Y. Zaltzman, E.L. Marcus, The effect of body position on pulmonary function: a systematic review, *BMC Pulm. Med.* 18 (2018) 159, <https://doi.org/10.1186/s12890-018-0723-4>.
- [12] Haag-Streit Group. In-Check Dial G16. https://www.haag-streit.com/clement-clarke/products/inhaler-technique/in-check-dial-g16/?no_cache=1, 2022 (Accessed 24 January 2022).
- [13] M. J. Sanders. Guiding inspiratory flow: Development of the In-Check DIAL G16, a tool for improving inhaler technique. *Pulm. Med.* (2017) 1495867, <https://doi.org/10.1155/2017/1495867>.
- [14] M.R. Miller, J. Hankinson, V. Brusasco, F. Burgos, R. Casaburi, A. Coates, et al., Standardisation of spirometry. *Eur. Respir. J.* 26 (2005) 319–338, <https://doi.org/10.1183/09031936.05.00034805>.
- [15] M. Krotkiewski, P. Björntorp, L. Sjöström, U. Smith, Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution, *J. Clin. Invest.* 72 (1983) 1150–1162, <https://doi.org/10.1172/JCI111040>.

- [16] P.C. Austin, Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research, *Commun. Stat. Simul. Comput.* 38 (2009) 1228–1234, <https://doi.org/10.1080/03610910902859574>.
- [17] M.E. Broeders, J. Molema, W.C. Hop, N.A. Vermue, H.T. Folgering, The course of inhalation profiles during an exacerbation of obstructive lung disease, *Respir. Med.* 98 (2004) 1173–1179, <https://doi.org/10.1016/j.rmed.2004.04.010>.
- [18] R.W. Dal Negro, Dry powder inhalers and the right things to remember: a concept review, *Multidiscip. Respir. Med.* 10 (2015) 13, <https://doi.org/10.1186/s40248-015-0012-5>.
- [19] P.N.R. Dekhuijzen, M. Batsiou, L. Bjermer, S. Bosnic-Anticevich, H. Chrystyn, A. Papi, et al., Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: effect of drug, dose, and device, *Respir. Med.* 120 (2016) 54–63, <https://doi.org/10.1016/j.rmed.2016.09.015>.
- [20] D.B. Price, M. Román-Rodríguez, R.B. McQueen, S. Bosnic-Anticevich, V. Carter, K. Gruffydd-Jones, et al., Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes, *J. Allergy Clin. Immunol. Pract.* 5 (2017) 1071–1081, <https://doi.org/10.1016/j.jaip.2017.01.004>.
- [21] L.D. Snyder, G. Safioti, M. Reich, M. Neely, N. Lugogo, R.A. Pleasants, T. Li, L. Granovsky, M. DePietro M, Objective assessment of rescue medication use and inhalation characteristics of COPD patients recorded by the electronic ProAir Digihaler, *Am. J. Respir. Crit. Care Med.* 201 (2020) A4305.
- [22] M.E. Broeders, J. Molema, W.C. Hop, N.A. Vermue, H.T. Folgering, The course of inhalation profiles during an exacerbation of obstructive lung disease, *Respir. Med.* 98 (12) (2004) 1173–1179, <https://doi.org/10.1016/j.rmed.2004.04.010>, 2004.

- [23] Watz, H., Tetzlaff, K., Magnussen, H. et al. Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial. *Respir. Res.* 19, 251. doi: 10.1186/s12931-018-0944-3.
- [24] R.S. Harris, Tracheal extension in respiration, *Thorax* 14 (1959) 201–210, <https://doi.org/10.1136/thx.14.3.201>.
- [25] G.M. Vilke, T.C. Chan, T. Neuman, J.L. Clausen, Spirometry in normal subjects in sitting, prone, and supine positions, *Respir. Care* 45 (2000) 407–410.
- [26] P. Weiner, M. Weiner, Inspiratory muscle training may increase peak inspiratory flow in chronic obstructive pulmonary disease, *Respiration* 73 (2006) 151–156, <https://doi.org/10.1159/000088095>.
- [27] B. Morrow, J. Brink, S. Grace, L. Pritchard, A. Lupton-Smith, The effect of positioning and diaphragmatic breathing exercises on respiratory muscle activity in people with chronic obstructive pulmonary disease, *S. Afr. J. Physiother.* 72 (2016) 315, <https://doi.org/10.4102/sajp.v72i1.315>.
- [28] R. Gosselink, Breathing techniques in patients with chronic obstructive pulmonary disease (COPD), *Chron. Respir. Dis.* 1 (2004) 163–172, <https://doi.org/10.1191/1479972304cd020rs>.
- [29] A.F. Elbehairy, A. Faisal, H. McIsaac, N.J. Domnik, K.M. Milne, M.D. James, J.A. Neder, et al., Mechanisms of orthopnoea in patients with advanced COPD, *Eur. Respir. J.* 57 (2021) 2000754, <https://doi.org/10.1183/13993003.00754-2020>
- [30] K.G. Nielsen, M. Skov, B. Klug, M. Ifversen, H. Bisgaard.. Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizer, *Eur. Respir. J.* 10 (1997) 2105–2109, <https://doi.org/10.1183/09031936.97.10092105>

[31] ADVAIR DISKUS. Prescribing Information. GlaxoSmithKline; 2023.

https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Advair_Diskus/pdf/ADVAIR-DISKUS-PI-PIL-IFU.PDF (Accessed 08 November 2023).

[32] BREO ELLIPTA. Prescribing Information. GlaxoSmithKline; 2023.

https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Breo_Ellipta/pdf/BREO-ELLIPTA-PI-PIL-IFU.PDF (Accessed 08 November 2023).

Table 1 Baseline demographic, clinical, and pulmonary characteristics.

Variable	Mean (SD) or n (%) ^a
	n = 76
Age, years	65.2 (8.77)
Race, White ^a	66 (87)
Sex, female ^a	42 (55)
BMI, kg/m ²	28.8 (7.26)
BMI categories ^a , kg/m ²	
<18.5	3 (4)
18.5 to <25	24 (32)
25 to <30	21 (28)
30 to <35	13 (17)
35 to <40	11 (14)
40+	4 (5)
Waist-to-hip ratio	1.03 (0.17)
Smoking status ^a	
Current	27 (36)
Former	49 (64)
Pack-years smoked	61.4 (39.1)
CAT score	23.3 (7.48)
mMRC score	2.76 (1.07)
Pre-BD	
FEV ₁ /FVC ratio	0.51 (0.11)
FEV ₁	
Absolute, L	1.21 (0.42)
% predicted	45.0 (14.6)
FVC	
Absolute, L	2.45 (0.72)
% predicted	68.8 (16.3)
PIF	
In-Check™ DIAL, L/min	69.0 (15.4)
R2 DPI (n=57)	75.8 (10.4)
R5 DPI (n=13)	49.8 (9.13)

Variable	Mean (SD) or n (%) ^a
	n = 76
R2 and R5 (n=6)	45.8 (3.76)
Spirometry, L/min	182 (67.2)
R2 DPI (n=38)	187.2 (67.4)
R5 DPI (n=13)	178.5 (63.1)
R2 and R5 (n=5)	154.9 (82.4)
Post-BD	
FEV₁/FVC ratio	0.53 (0.12)
FEV₁	
Absolute, L	1.28 (0.43)
% predicted	48.7 (15.1)
FVC	
Absolute, L	2.49 (0.76)
% predicted	72.4 (0.18)
PIF	
In-Check™ DIAL, L/min	75.3 (16.6)
R2 DPI (n=57)	81.8 (12.6)
R5 DPI (n=13)	54.3 (11.1)
R2 and R5 (n=6)	57.7 (9.91)
Spirometry, L/min	179 (72.8)
R2 DPI (n=35)	175.3 (71.0)
R5 DPI (n=12)	197.3 (71.2)
R2 and R5 (n=5)	159.2 (95.3)
Resistance class of inhaler	
R5 ^a	13 (17)
R2 ^a	57 (75)
Both R2 and R5 ^a	6 (8)

Data were missing for spirometry testing due to the impact of the COVID-19 pandemic. n (%) with the available spirometry data includes pre-BD FEV₁, FVC (n = 75); pre-BD PIF (spirometry; n = 56); post-BD FEV₁, FVC, FEV₁/FVC (n = 63); and post-BD spirometry PIF (n = 52).

^an (%).

BD = bronchodilator; BMI = body mass index; CAT = COPD Assessment Test; COPD = chronic obstructive pulmonary disease; DPI = dry powder inhaler; FEV₁ = forced expiratory volume in 1 second; FVC = forced vital capacity; mMRC = modified Medical Research Council; PIF = peak inspiratory flow; R2 = low-medium resistance; R5 = high resistance; SD = standard deviation.

Table 2 Percentage decline in PIF between physical positions using R2 and R5 DPIs.

Positional change	DPI resistance	n = 82 ^a	>10% decline n (%)	>15% decline n (%)	>20% decline n (%)
Standing to sitting	R2	63	10 (16)	4 (6)	0 (0)
	R5	19	6 (32)	3 (16)	0 (0)
Standing to semi-upright	R2	63	31 (50)	8 (12)	3 (5)
	R5	19	10 (53)	6 (32)	3 (16)
Sitting to semi-upright	R2	63	11 (18)	7 (11)	2 (3)
	R5	19	6 (32)	3 (16)	1 (5)

^aSix participants contributed to both the R2 and R5 groups, as they were on both inhaler types at enrollment.

DPI = dry powder inhaler; PIF = peak inspiratory flow; R2 = low-medium resistance; R5 = high resistance.

Table 3 Differences in characteristics between >10% vs. ≤10% PIF decline standing to semi-upright (R2 DPIs).

Characteristic	>10% decline	≤10% decline	Standardized difference
	n = 31	n = 32	
Age, years	65.1 (8.71)	66.5 (8.59)	0.166
Race, White ^a	28 (90)	29 (90)	−0.089
Sex, female ^a	16 (52)	19 (59)	0.15
BMI, kg/m ²	29.3 (7.66)	28.7 (6.94)	−0.08
BMI categories ^a , kg/m ²			
<18.5	0 (0)	1 (3)	
18.5 to <25	9 (29)	13 (41)	
25 to <30	11 (35)	4 (13)	
30 to <35	6 (19)	6 (19)	
35 to <40	3 (10)	7 (22)	
40+	2 (6)	1 (3)	−0.03
Waist-to-hip ratio	1.02 (0.94)	1.05 (0.25)	0.16
Current smoking ^a	13 (42)	9 (28)	−0.29
Pack-years smoked	61.1 (39.1)	60.9 (39.9)	−0.007
CAT score	23.2 (8.22)	22.2 (6.23)	−0.15
mMRC score	2.61 (1.09)	2.78 (1.10)	0.15
Pre-BD			
FEV ₁ /FVC ratio	0.51 (0.11)	0.52 (0.11)	0.13
FEV ₁			
Absolute, L	1.28 (0.45)	1.21 (0.36)	−0.16
% predicted	46.4 (14.3)	46.6 (41.5)	0.02
FVC			
Absolute, L	2.60 (0.76)	2.42 (0.67)	−0.25
% predicted	70.8 (14.2)	70.6 (17.5)	−0.008
PIF			
In-Check™ DIAL, L/min	72.3 (14.2)	73.6 (12.6)	0.09
Spirometry, L/min	177 (70.7)	189 (68.4)	0.17
Post-BD			

Characteristic	>10% decline	≤10% decline	Standardized difference
	n = 31	n = 32	
FEV₁/FVC ratio	0.53 (0.11)	0.55 (0.13)	0.14
FEV₁			
Absolute, L	1.32 (0.46)	1.31 (0.37)	−0.017
% predicted	49.2 (14.0)	51.7 (14.6)	0.17
FVC			
Absolute, L	2.55 (0.72)	2.56 (0.78)	0.014
% predicted	73.0 (14.4)	76.5 (18.6)	0.21
PIF			
In-Check™ DIAL, L/min	79.3 (15.5)	79.5 (13.2)	0.01
Spirometry, L/min	166 (81.9)	180 (64.6)	0.19

Data were missing for spirometry testing due to the impact of the COVID-19 pandemic. n (%) with the available spirometry data includes pre-BD FEV₁ and FVC (n = 31 in each group), pre-BD PIF (spirometry; n = 22 in the >10% decline group; n = 21 in the ≤10% decline group), post-BD FEV₁ and FVC (n = 24 in the >10% decline group; n = 27 in the ≤10% decline group), and post-BD PIF (spirometry; n = 20 in each group).

^aData are presented as n (%). At all other instances, data are presented as mean (standard deviation). Bolded standardized differences indicate values $\geq \pm 0.10$.

BD = bronchodilator; BMI = body mass index; CAT = COPD Assessment Test; COPD = chronic obstructive pulmonary disease; DPI = dry powder inhaler; FEV₁ = forced expiratory volume in 1 second; FVC = forced vital capacity; mMRC = modified Medical Research Council; PIF = peak inspiratory flow; R2 = low-medium resistance.

Table 4 Differences in characteristics between >10% vs. ≤10% PIF decline standing to semi-upright (R5 DPIs).

Variable	>10% decline	≤10% decline	Standardized difference
	n = 10	n = 9	
Age, years	63.2 (8.44)	63.3 (8.74)	0.01
Race, White ^a	8 (80)	6 (67)	−0.29
Sex, female ^a	8 (80)	4 (44)	−0.74
BMI, kg/m ²	28.2 (7.34)	28.6 (7.85)	0.04
BMI categories ^a , kg/m ²			
<18.5	1 (10)	1 (11)	
18.5 to <25	2 (20)	2 (22)	
25 to <30	3 (30)	3 (33)	
30 to <35	1 (10)	2 (22)	
35 to <40	3 (30)	0 (0)	
40+	0 (0)	1 (11)	−0.13
Waist-to-hip ratio	0.95 (0.06)	1.03 (0.12)	0.88
Current smoking ^a	4 (40)	4 (44)	0.085
Pack-years smoked	53.8 (37.1)	61.8 (39.1)	0.21
CAT score	22.9 (7.34)	27.2 (7.51)	0.58
mMRC score	2.60 (0.84)	3.33 (0.71)	0.94
Pre-BD			
FEV ₁ /FVC ratio	0.52 (0.08)	0.45 (0.13)	−0.64
FEV ₁			
Absolute, L	0.97 (0.29)	1.13 (0.51)	0.39
% predicted	41.7 (16.1)	40.8 (18.0)	−0.05
FVC			
Absolute, L	1.87 (0.46)	2.45 (0.76)	0.92
% predicted	59.8 (16.1)	66.6 (18.1)	0.40
PIF			
In-Check™ DIAL, L/min	46.3 (5.46)	51.1 (9.74)	0.61
Spirometry, L/min	164.5 (64.9)	181.3 (73.5)	0.24
Post-BD			

Variable	>10% decline	≤10% decline	Standardized difference
	n = 10	n = 9	
FEV₁/FVC ratio	0.54 (0.08)	0.48 (0.18)	−0.39
FEV₁			
Absolute, L	1.04 (0.30)	1.23 (0.57)	0.43
% predicted	44.2 (15.2)	44.1 (20.0)	−0.005
FVC			
Absolute, L	1.93 (0.38)	2.61 (0.94)	0.96
% predicted	61.7 (13.9)	70.4 (21.3)	0.48
PIF			
In-Check™ DIAL, L/min	52 (6.73)	59.8 (13.2)	0.74
Spirometry, L/min	173 (74.0)	205 (85.4)	0.40

Data were missing for spirometry testing owing to the impact of the COVID-19 pandemic. n (%) with the available spirometry data includes pre-BD FEV₁ and FVC (n = 10 in the >10% decline group; n = 9 in the ≤10% decline group), pre-BD PIF (spirometry; n = 10 in the >10% decline group; n = 8 in the ≤10% decline group), post-BD FEV₁ and FVC (n = 10 in the >10% decline group; n = 8 in the ≤10% decline group), and post-BD PIF (spirometry; n = 10 in the >10% decline group; n = 7 in the ≤10% decline group).


^aData are presented as n (%). At all other instances, data are presented as mean (standard deviation). Bolded standardized differences indicate values >±0.10.

BD = bronchodilator; BMI = body mass index; CAT = COPD Assessment Test; COPD = chronic obstructive pulmonary disease; DPI = dry powder inhaler; FEV₁ = forced expiratory volume in 1 second; FVC = forced vital capacity; mMRC = modified Medical Research Council; PIF = peak inspiratory flow; R5 = high resistance.

Fig. 1. Distributional (box and whisker) plots of PIF by physical position and DPI.

^aPIF in the semi-upright position was significantly lower than that in the sitting and standing positions ($P < 0.0001$).

^bPIF in the semi-upright position was significantly lower than that in the standing position ($P = 0.002$).




The box indicates the IQR (25th and 75th percentiles). The lower and upper lines (whiskers) indicate the furthest observation, that is, within one and a half times the IQR of the lower or upper end of the box. The median PIF for each group is represented by the horizontal bar inside the box. All PIF measurements analyzed were measured using the In-Check™ DIAL. The dot denotes an outlier.

DPI = dry powder inhaler; IQR = interquartile range; PIF = peak inspiratory flow; R2 = low-medium resistance; R5 = high resistance.

Fig. 2. Scatter plots showing correlations of PIF for the physical positions.

Scatter plots for (a) standing vs. sitting, (b) standing vs. semi-upright, and (c) sitting vs. semi-upright for DPIs against R2 (orange) and R5 (blue) internal resistance. Black line represents identity line/line of equality ($y=x$). R2: standing vs. sitting (Spearman's rho 0.875; $P < 0.0001$), standing vs. semi-upright (Spearman's rho 0.887; $P < 0.0001$), and sitting vs. semi-upright (Spearman's rho 0.888; $P < 0.0001$). R5: standing vs. sitting (Spearman's rho 0.7132; $P = 0.0006$), standing vs. semi-upright (Spearman's rho 0.717; $P = 0.0005$), and sitting vs. semi-upright (Spearman's rho 0.682; $P = 0.0013$).

DPI = dry powder inhaler; PIF = peak inspiratory flow; R2 = low-medium resistance; R5 = high resistance.



Online Supplement

Supplementary Table 1. Baseline Demographic, Clinical, and Pulmonary Characteristics Stratified by Inhaler Device Type at Enrollment.

Variable	R2	R5	R2 and R5
	n = 57	n = 13	n = 6
Age, years	65.8 (8.89)	62.3 (9.31)	65.5 (5.82)
Race, White ^a	52 (91)	10 (77)	4 (67)
Sex, female ^a	30 (53)	7 (54)	5 (83)
BMI, kg/m ²	29.0 (7.29)	27.9 (7.57)	29.4 (7.50)
BMI category ^a , kg/m ²			
<18.5	1 (2)	2 (15)	0 (0)
18.5 to <25	20 (35)	2 (15)	2 (33)
25 to <30	15 (26)	6 (46)	0 (0)
30 to <35	10 (18)	1 (8)	2 (33)
35 to <40	8 (14)	1 (8)	2 (33)
40+	3 (5)	1 (8)	0 (0)
Waist-to-hip ratio	1.04 (0.19)	0.99 (0.10)	0.98 (0.12)
Smoking status ^a			
Current	19 (33)	5 (38)	3 (50)
Former	38 (67)	8 (62)	3 (50)
Pack-years smoked	62.7 (39.9)	63.5 (40.0)	44.8 (29.1)
CAT score	22.7 (7.44)	26.0 (8.30)	22.3 (5.4)
mMRC score	2.70 (1.13)	3.08 (0.95)	2.67 (0.52)
Pre-BD			
FEV ₁ /FVC ratio	0.52 (0.11)	0.47 (0.11)	0.52 (0.10)
FEV ₁			
Absolute, L	1.26 (0.41)	1.04 (0.46)	1.08 (0.27)
% predicted	46.3 (13.7)	37.9 (15.3)	48.5 (18.3)
FVC			
Absolute, L	2.54 (0.72)	2.16 (0.72)	2.11 (0.63)
% predicted	70.8 (15.8)	59.9 (16.7)	69.7 (16.9)

PIF			
In-Check™ DIAL, L/min	75.8 (10.4)	49.8 (9.13)	45.8 (3.76)
Spirometry, L/min	187.2 (67.4)	178.5 (63.1)	154.9 (82.4)
Post-BD			
FEV₁/FVC ratio	0.54 (0.12)	0.50 (0.13)	0.55 (0.12)
FEV₁			
Absolute, L	1.33 (0.42)	1.12 (0.51)	1.13 (0.28)
% predicted	50.5 (14.0)	40.8 (16.7)	50.8 (16.8)
FVC			
Absolute, L	2.60 (0.75)	2.24 (0.82)	2.22 (0.67)
% predicted	75.1 (17.0)	61.8 (17.7)	73.2 (16.0)
PIF			
In-Check™ DIAL, L/min	81.8 (12.6)	54.3 (11.1)	57.7 (9.91)
Spirometry, L/min	175.3 (71.0)	197.3 (71.2)	159.2 (95.3)

Data are missing for spirometry testing due to the impact of the COVID-19 pandemic. n (%) with the available spirometry data includes pre-BD FEV₁, FVC, FEV₁/FVC (n = 56, R2; n = 13, R5; n = 6, R2 and R5), pre-BD PIF (spirometry; n = 38, R2; n = 13, R5; n = 5, R2 and R5), post-BD FEV₁, FVC, FEV₁/FVC (n = 45, R2; n = 12, R5; n = 6, R2 and R5), and post-BD spirometry PIF (n = 35, R2; n = 12; R5; n = 5, R2, and R5).

^an (%); other values are mean (SD).

BD = bronchodilator; BMI = body mass index; CAT = Chronic Obstructive Pulmonary Disease Assessment Test; FEV₁ = forced expiratory volume in 1 second; FVC = forced vital capacity; mMRC = modified Medical Research Council; PIF = peak inspiratory flow; R2 = low-medium resistance; R5 = high resistance; SD = standard deviation.